Hidradenitis Suppurativa Written Action Plan

Hidradenitis Suppurativa Clinical Trial

— HSWAP  

Official title:

Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04230291
• Other study ID #: 1910019510
• Status: Terminated
• Phase: N/A
• Start date: February 1, 2020
• Est. completion date: March 17, 2020

Study information

• Verified date: September 2020
• Source: University of Arizona
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being conducted to evaluate if a written action plan for hidradenitis suppurativa (HS) will help patients with hidradenitis suppurativa gain a better understanding of the condition and how to manage the condition on a daily basis compared to a routine verbal consultation.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: March 17, 2020
• Est. primary completion date: March 17, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Has a diagnosis of HS

Exclusion Criteria:

• Has been exposed to a written action plan for HS before

Related Conditions & MeSH terms

• Hidradenitis
• Hidradenitis Suppurativa

Intervention

Behavioral:
• Verbal consultation
Verbal consultation only without written information before receiving written action plan
• Written Action Plan
Written handout of treatment plan and disease management strategies

Locations

Country	Name	City	State
United States	University of Arizona	Tucson	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
University of Arizona	University of Arkansas

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visits to high-cost care settings	Number of visits to ER, urgent care, or hospitalizations because of HS	12 months